JP2006528210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006528210A5 JP2006528210A5 JP2006529602A JP2006529602A JP2006528210A5 JP 2006528210 A5 JP2006528210 A5 JP 2006528210A5 JP 2006529602 A JP2006529602 A JP 2006529602A JP 2006529602 A JP2006529602 A JP 2006529602A JP 2006528210 A5 JP2006528210 A5 JP 2006528210A5
- Authority
- JP
- Japan
- Prior art keywords
- mineral
- powder
- weight
- water
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 39
- 239000011707 mineral Substances 0.000 claims description 38
- 239000000843 powder Substances 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 26
- 235000012239 silicon dioxide Nutrition 0.000 claims description 21
- 239000010459 dolomite Substances 0.000 claims description 18
- 229910000514 dolomite Inorganic materials 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 239000010453 quartz Substances 0.000 claims description 12
- 239000011435 rock Substances 0.000 claims description 12
- 239000010457 zeolite Substances 0.000 claims description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 9
- 229910021536 Zeolite Inorganic materials 0.000 claims description 9
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 9
- 239000008158 vegetable oil Substances 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 7
- 229920000609 methyl cellulose Polymers 0.000 claims description 7
- 239000001923 methylcellulose Substances 0.000 claims description 7
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims description 6
- 235000019485 Safflower oil Nutrition 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 5
- 235000005713 safflower oil Nutrition 0.000 claims description 5
- 239000003813 safflower oil Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- -1 polydimethylsiloxane Polymers 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 description 17
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 15
- 229910052710 silicon Inorganic materials 0.000 description 15
- 239000010703 silicon Substances 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 239000011343 solid material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 238000013021 overheating Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000011856 silicon-based particle Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910004283 SiO 4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003345 natural gas Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10323759A DE10323759A1 (de) | 2003-05-22 | 2003-05-22 | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen |
| PCT/DE2004/001047 WO2004105777A1 (de) | 2003-05-22 | 2004-05-18 | Steinmehl, insbesondere dolomitsteinmehlheilmittel, zur behandlung von kresbserkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006528210A JP2006528210A (ja) | 2006-12-14 |
| JP2006528210A5 true JP2006528210A5 (enExample) | 2007-07-05 |
Family
ID=33441300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006529602A Withdrawn JP2006528210A (ja) | 2003-05-22 | 2004-05-18 | 岩粉、好適にはドロマイト岩粉をベースとした癌治療のための薬 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060251738A1 (enExample) |
| EP (1) | EP1628671A1 (enExample) |
| JP (1) | JP2006528210A (enExample) |
| CN (1) | CN1795002A (enExample) |
| AU (1) | AU2004243523A1 (enExample) |
| CA (1) | CA2525908A1 (enExample) |
| DE (1) | DE10323759A1 (enExample) |
| RU (1) | RU2005140098A (enExample) |
| WO (1) | WO2004105777A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE112006002042A5 (de) * | 2005-05-18 | 2008-04-30 | Mijo Ljubicic | Mikronisierte mineralische Materialien und deren Herstellung |
| WO2007008711A2 (en) * | 2005-07-08 | 2007-01-18 | George Mason University | Synthetic nanoparticle soil materials |
| KR101199897B1 (ko) | 2011-11-14 | 2012-11-09 | 권태동 | 천연 광물 및 이의 용해물을 유효성분으로 함유하는 암 예방 및 치료용 조성물 |
| KR101199895B1 (ko) | 2011-11-14 | 2012-11-09 | 권태동 | 천연 광물 및 이의 용해물을 유효성분으로 함유하는 당뇨병 예방 및 치료용 조성물 |
| DE102013013029A1 (de) * | 2013-08-05 | 2015-02-05 | Ernst Fekete | Lobbyist-Zellschutz PNI (Psychoneuroimmunium) |
| CN104606261B (zh) * | 2015-03-05 | 2018-02-09 | 潘友长 | 一种沸石药物组合物及其制备方法和用途 |
| RU2629338C1 (ru) * | 2016-08-26 | 2017-08-28 | Алам Джан | Фармацевтическая композиция для стабилизации гомеостаза и купирования патологических процессов в организме и инъекционная лекарственная форма этой композиции |
| KR101996383B1 (ko) | 2017-12-01 | 2019-07-04 | (주)카데시인코퍼레이션 | 퓨리톤을 유효성분으로 포함하는 항암용 조성물 |
| CN108403755A (zh) * | 2018-05-03 | 2018-08-17 | 北京胜泰生物医药科技有限公司 | 一种沸石药物的组合、制备及用途 |
| US20230225386A1 (en) * | 2021-12-30 | 2023-07-20 | H2 Universe Llc | Hydrogen-generating composition for dietary and agricultural applications |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU200933B (en) * | 1988-12-22 | 1990-09-28 | Jozsef Markus | Process for producing pharmaceutical composition for profilacting and treating osteoporosis |
| DE19530882A1 (de) * | 1995-08-11 | 1997-02-13 | Thomas Dr Ing Loeser | Arzneimittel zur Vorbeugung, Begleittherapie und Heilung von Geschwulstkrankheiten |
| DE19603477A1 (de) * | 1996-01-31 | 1997-08-07 | Klaus Dr Med Reuter | Tumormittel |
| DE59707063D1 (de) * | 1996-03-25 | 2002-05-23 | Bauer Wulf | Heilmittel zur äusserlichen anwendung und verwendung einer wässrigen öl-emulsion für ein derartiges heilmittel |
| DE19750328A1 (de) * | 1997-11-13 | 1999-05-20 | Klaus Dr Med Reuter | Tumormittel |
| US6251439B1 (en) * | 1998-12-16 | 2001-06-26 | Trustee Of The Dartmouth College | Composition and method for reducing the risk of carcinogenesis |
| EP1107826A1 (de) * | 1999-04-26 | 2001-06-20 | Tihomir Lelas | Vorrichtung zum mikronisieren von materialien |
| EP1129715A1 (de) * | 2000-02-25 | 2001-09-05 | Werner Dr. Reichen | Anwendung von Magnesium, Kalzium und Silizium zur Heilung verschiedener Krankheiten und zum allgemeinen Wohlbefinden |
| CA2419434A1 (en) * | 2000-09-19 | 2003-02-07 | Daiichi Pharmaceutical Co., Ltd. | Medicinal composition |
| JP2003063951A (ja) * | 2001-08-23 | 2003-03-05 | Nonogawa Shoji Kk | 錠剤及びその製造方法 |
| DE10323758A1 (de) * | 2003-05-22 | 2004-12-16 | Bauer, Wulf, Dr. | Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen |
-
2003
- 2003-05-22 DE DE10323759A patent/DE10323759A1/de not_active Withdrawn
-
2004
- 2004-05-18 JP JP2006529602A patent/JP2006528210A/ja not_active Withdrawn
- 2004-05-18 US US10/558,099 patent/US20060251738A1/en not_active Abandoned
- 2004-05-18 EP EP04733527A patent/EP1628671A1/de not_active Withdrawn
- 2004-05-18 CA CA002525908A patent/CA2525908A1/en not_active Abandoned
- 2004-05-18 WO PCT/DE2004/001047 patent/WO2004105777A1/de not_active Ceased
- 2004-05-18 RU RU2005140098/15A patent/RU2005140098A/ru unknown
- 2004-05-18 AU AU2004243523A patent/AU2004243523A1/en not_active Abandoned
- 2004-05-18 CN CNA2004800140425A patent/CN1795002A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2778441C (en) | Hydrated microparticles of apigenin and/or luteolin with improved solubility | |
| US20090291144A1 (en) | Therapeutic and Prophylactic Compositions Including Catalytic Biomimetic Solids and Methods to Prepare and Use Them | |
| AU2013345062B2 (en) | Process for making agglomerates using acoustic mixing technology | |
| EP3436033B1 (en) | A poly-oxygenated metal hydroxide comprising a clathrate that increases oxygen levels in mammalian tissues | |
| CN109876008A (zh) | 一种用于肿瘤治疗的药物及其制备方法和应用 | |
| JP2006528210A5 (enExample) | ||
| JP2006528210A (ja) | 岩粉、好適にはドロマイト岩粉をベースとした癌治療のための薬 | |
| Paladhi et al. | Nanoscale diamond-based formulation as an immunomodulator and potential therapeutic for lymphoma | |
| JP2019529354A (ja) | ナノシリカ粒子を含む組成物および療法のためにｔリンパ球を活性化する方法におけるそれらの使用 | |
| JP2006528211A (ja) | 癌治療用の内服用の薬 | |
| CA2780771C (en) | Pharmaceutical composition having antimicrobial and fast-healing activity for external administration, process for preparing sames | |
| Mansingh et al. | Herbal Nanoparticles: A commitment towards contemporary approach | |
| KR20230116674A (ko) | 안정화된 테트라하이드로커큐민을 함유하는 아토피 피부염 개선용 식품조성물 | |
| Bhosale et al. | Nanodiamonds: a new-fangled drug delivery system | |
| JP2020200302A (ja) | 虚血性脳血管障害に伴う障害の予防又は治療剤 | |
| Wu et al. | Curcumin nanoparticles and the therapeutic potential of curcumin for musculoskeletal disorders. | |
| CN101028281B (zh) | 纳米胶体果胶铋及其颗粒剂药物 | |
| WO2007000939A1 (ja) | 局所炎症治療用薬剤 | |
| Roohi et al. | Royal Jelly Nanoparticle Alleviates Experimental Model of Breast Cancer Through Suppressing Regulatory T Cells and Upregulating TH1 Cells. | |
| Martin | Contribution of bioavailable silicon in human health | |
| Ajoolabady et al. | Melatonin-Based Therapeutics for Atherosclerotic Lesions and Beyond: Focusing on Macrophage Mitophagy | |
| RU2278671C2 (ru) | Средство для поддерживающей терапии | |
| RU2730477C1 (ru) | Способ получения биологически активной фармацевтической субстанции для питания внеклеточного матрикса и профилактики заболеваний опорно-двигательного аппарата и барьерных функций органов дыхания и пищеварения | |
| RU2268053C1 (ru) | Способ лечения гипокальциемий, остеопорозов, переломов | |
| KR101986510B1 (ko) | 금나노 입자가 분산되어 있는 숙취해소제, 건강보조식품 및 그 제조방법 |